|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
49,740,000 |
Market
Cap: |
2.83(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$19.95 - $56.99 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Morphic is a biopharmaceutical company. Co. is applying its proprietary insights into integrins to discover and develop a pipeline of oral small-molecule integrin therapeutics. Integrins are a target class with various approved injectable blockbuster drugs for the treatment of chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. Co. is developing its pipeline, including its main product candidate, MORF-057, an a4ss7-specific integrin inhibitor affecting inflammation, into clinical development for the treatment of inflammatory bowel disease. Co. has also developed selective oral avss6-specific integrin inhibitors including MORF-720 and MORF-627.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
4,776 |
1,054,776 |
Total Buy Value |
$0 |
$0 |
$98,239 |
$47,348,239 |
Total People Bought |
0 |
0 |
2 |
3 |
Total Buy Transactions |
0 |
0 |
2 |
3 |
Total Shares Sold |
125,790 |
125,790 |
161,666 |
443,623 |
Total Sell Value |
$7,018,609 |
$7,018,609 |
$8,004,865 |
$22,106,148 |
Total People Sold |
5 |
5 |
5 |
5 |
Total Sell Transactions |
5 |
5 |
10 |
34 |
End Date |
2024-06-23 |
2024-03-22 |
2023-09-22 |
2022-09-22 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Stampacchia Otello |
Director |
|
2021-03-19 |
4 |
AS |
$61.92 |
$1,055,174 |
D/D |
(16,629) |
2,434,742 |
|
- |
|
Stampacchia Otello |
Director |
|
2021-03-18 |
4 |
AS |
$63.00 |
$1,243,904 |
D/D |
(19,472) |
2,451,371 |
|
- |
|
Stampacchia Otello |
Director |
|
2021-03-17 |
4 |
AS |
$63.72 |
$1,052,362 |
D/D |
(16,381) |
2,470,843 |
|
- |
|
Linde Peter |
Chief Medical Officer |
|
2021-03-16 |
4 |
AS |
$63.65 |
$768,201 |
D/D |
(12,000) |
10,600 |
|
- |
|
Linde Peter |
Chief Medical Officer |
|
2021-03-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
21,743 |
22,600 |
|
- |
|
Devaul William |
General Counsel and Secretary |
|
2021-03-16 |
4 |
AS |
$63.57 |
$897,693 |
D/D |
(14,027) |
4,206 |
|
- |
|
Devaul William |
General Counsel and Secretary |
|
2021-03-16 |
4 |
OE |
$4.32 |
$60,597 |
D/D |
14,027 |
18,233 |
|
- |
|
Stampacchia Otello |
Director |
|
2021-03-16 |
4 |
AS |
$62.52 |
$1,782,898 |
D/D |
(27,859) |
2,487,164 |
|
- |
|
Rogers Bruce |
Chief Scientific Officer |
|
2021-03-15 |
4 |
AS |
$63.97 |
$558,181 |
D/D |
(8,509) |
89,849 |
|
- |
|
Devaul William |
General Counsel and Secretary |
|
2021-03-15 |
4 |
AS |
$63.84 |
$3,023,971 |
D/D |
(45,973) |
4,206 |
|
- |
|
Devaul William |
General Counsel and Secretary |
|
2021-03-15 |
4 |
OE |
$4.32 |
$198,603 |
D/D |
45,973 |
50,179 |
|
- |
|
Stampacchia Otello |
Director |
|
2021-03-15 |
4 |
AS |
$63.97 |
$2,407,573 |
D/D |
(36,532) |
2,515,023 |
|
- |
|
Schegerin Marc |
CFO and COO |
|
2021-03-08 |
4 |
B |
$63.50 |
$190,514 |
D/D |
3,000 |
6,379 |
2.74 |
- |
|
Springer Timothy A |
Director |
|
2021-03-05 |
4 |
B |
$70.00 |
$7,000,000 |
I/I |
100,000 |
475,019 |
2.25 |
- |
|
Goyal Vikas |
Director |
|
2021-03-05 |
4 |
B |
$70.00 |
$70,000 |
D/D |
1,000 |
1,000 |
2.39 |
- |
|
Stampacchia Otello |
Director |
|
2021-03-01 |
4 |
AS |
$45.49 |
$324,446 |
D/D |
(7,064) |
2,551,555 |
|
- |
|
Stampacchia Otello |
Director |
|
2021-02-26 |
4 |
AS |
$32.87 |
$670,079 |
D/D |
(19,246) |
2,558,619 |
|
- |
|
Stampacchia Otello |
Director |
|
2021-02-25 |
4 |
AS |
$33.46 |
$326,182 |
D/D |
(9,679) |
2,577,865 |
|
- |
|
Stampacchia Otello |
Director |
|
2021-02-24 |
4 |
AS |
$34.27 |
$104,249 |
D/D |
(2,998) |
2,587,544 |
|
- |
|
Stampacchia Otello |
Director |
|
2021-02-23 |
4 |
AS |
$33.75 |
$256,064 |
D/D |
(7,550) |
2,590,542 |
|
- |
|
Stampacchia Otello |
Director |
|
2021-02-22 |
4 |
AS |
$34.80 |
$224,243 |
D/D |
(6,423) |
2,598,092 |
|
- |
|
Stampacchia Otello |
Director |
|
2021-02-19 |
4 |
AS |
$34.82 |
$157,801 |
D/D |
(4,436) |
2,604,515 |
|
- |
|
Stampacchia Otello |
Director |
|
2021-02-18 |
4 |
AS |
$34.83 |
$310,641 |
D/D |
(8,894) |
2,608,951 |
|
- |
|
Stampacchia Otello |
Director |
|
2021-02-17 |
4 |
AS |
$35.93 |
$260,924 |
D/D |
(7,262) |
2,617,845 |
|
- |
|
Stampacchia Otello |
Director |
|
2021-02-16 |
4 |
AS |
$36.42 |
$220,395 |
D/D |
(6,025) |
2,625,107 |
|
- |
|
366 Records found
|
|
Page 7 of 15 |
|
|